The CAR-T cells engineered to express IL-7 and CCL19 have been validated to increase the infiltration of peripheral CAR-T cells and dendritic cells and into tumor tissues and enhance the anti-tumor immune responses (168). Here, CCL19 is linked to neoplasm.